Literature DB >> 19132537

Polymeric matrix system for prolonged delivery of tramadol hydrochloride, part I: physicochemical evaluation.

H O Ammar1, M Ghorab, S A El-Nahhas, R Kamel.   

Abstract

Management of moderate or severe chronic pain conditions is the burden of clinicians dealing with patients trying to improve their quality of life and diminish their suffering. Although not a new opioid, tramadol has been recently rediscovered and widely used; this may be due to its favorable chronic safety and dependence profiles together with its high potency. Tramadol is a centrally acting analgesic with half-life of approximately 6 h; therefore, it requires frequent dosing. It is freely soluble in water; hence, judicious selection of retarding formulations is necessary. The current study is focused on the innovation of a novel, simple, monolayer, easy-to-use, cost-effective, and aesthetically acceptable bioadhesive transdermal delivery system overcoming the defects of the conventional "patch" as carrier system for tramadol, ensuring its adequate delivery, along with the physicochemical evaluation of the designed formulations. Monolithic tramadol matrix films of chitosan, different types of Eudragit, and binary mixtures of both were prepared. As a single-polymer film, chitosan film showed best properties except for somewhat high moisture uptake capacity, insufficient strength and rapid release, and permeation. Polymer blends were monitored in order to optimize both properties and performance. Promising results were obtained, with chitosan-Eudragit NE30D (1:1) film showing the most desirable combined, sufficiently rapid as well as prolonged release and permeation profiles along with satisfactory organoleptic and physicochemical properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132537      PMCID: PMC2663660          DOI: 10.1208/s12249-008-9167-0

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  46 in total

Review 1.  Passive skin penetration enhancement and its quantification in vitro.

Authors:  K Moser; K Kriwet; A Naik; Y N Kalia; R H Guy
Journal:  Eur J Pharm Biopharm       Date:  2001-09       Impact factor: 5.571

2.  Analysis of data on the medicament release from ointments.

Authors:  W I HIGUCHI
Journal:  J Pharm Sci       Date:  1962-08       Impact factor: 3.534

3.  Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration.

Authors:  P R Rao; P V Diwan
Journal:  Drug Dev Ind Pharm       Date:  1998-04       Impact factor: 3.225

4.  Preparation and evaluation of a chitosan salt-poloxamer 407 based matrix for buccal drug delivery.

Authors:  S Cafaggi; R Leardi; B Parodi; G Caviglioli; E Russo; G Bignardi
Journal:  J Control Release       Date:  2005-01-20       Impact factor: 9.776

5.  Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol.

Authors:  Perry Fung Chye Lim; Xiang Yang Liu; Lifeng Kang; Paul Chi Lui Ho; Yew Weng Chan; Sui Yung Chan
Journal:  Int J Pharm       Date:  2006-01-31       Impact factor: 5.875

6.  Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery.

Authors:  A Akhgari; F Farahmand; H Afrasiabi Garekani; F Sadeghi; T F Vandamme
Journal:  Eur J Pharm Sci       Date:  2006-03-28       Impact factor: 4.384

7.  Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions.

Authors:  Evangelos Karavas; Georgios Ktistis; Aristotelis Xenakis; Emmanouel Georgarakis
Journal:  Drug Dev Ind Pharm       Date:  2005-07       Impact factor: 3.225

Review 8.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

9.  Bioequivalence of marketed transdermal delivery systems for tulobuterol.

Authors:  Kakuji Tojo; Tomohiro Hikima
Journal:  Biol Pharm Bull       Date:  2007-08       Impact factor: 2.233

10.  Evaluation of carboxymethyl guar films for the formulation of transdermal therapeutic systems.

Authors:  S Narasimha Murthy; Shobha Rani R Hiremath; K L K Paranjothy
Journal:  Int J Pharm       Date:  2004-03-19       Impact factor: 5.875

View more
  5 in total

1.  Formulation of a novel tianeptine sodium orodispersible film.

Authors:  Doaa Ahmed El-Setouhy; Nevine Shawky Abd El-Malak; Nevine Shawky Abd El-Malak
Journal:  AAPS PharmSciTech       Date:  2010-06-08       Impact factor: 3.246

2.  Composite carbohydrate interpenetrating polyelectrolyte nano-complexes (IPNC) as a controlled oral delivery system of citalopram HCl for pediatric use: in-vitro/in-vivo evaluation and histopathological examination.

Authors:  Rabab Kamel; Haidy Abbas; Mona El-Naa
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

3.  Prunus armeniaca Gum-Alginate Polymeric Microspheres to Enhance the Bioavailability of Tramadol Hydrochloride: Formulation and Evaluation.

Authors:  Shazia Noureen; Sobia Noreen; Shazia Akram Ghumman; Fozia Batool; Huma Hameed; Sara Hasan; Fozia Noreen; Mervat A Elsherif; Syed Nasir Abbas Bukhari
Journal:  Pharmaceutics       Date:  2022-04-22       Impact factor: 6.525

4.  Effects of spray drying conditions on the physicochemical properties of the Tramadol-Hcl microparticles containing Eudragit(®) RS and RL.

Authors:  A S Patel; T Soni; V Thakkar; T Gandhi
Journal:  J Pharm Bioallied Sci       Date:  2012-03

5.  Optimization and characterization of chitosan films for transdermal delivery of ondansetron.

Authors:  Aslı Sedef Can; Meryem Sedef Erdal; Sevgi Güngör; Yıldız Özsoy
Journal:  Molecules       Date:  2013-05-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.